ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
22 3월 2023 - 9:30PM
ReShape Lifesciences Inc. (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health-solutions company, today announced that it will report its
financial results for the year ended December 31, 2022, including a
corporate update, on Wednesday, March 29, 2023, pre-market.
Management will host a conference call on March
29 at 8:00 am ET. A live webcast will be available on the “Events
and Presentations” section of ReShape’s website at:
https://ir.reshapelifesciences.com/events-and-presentations. To
access the call by phone, please register with the following
Registration Link, and dial-in details will be provided.
Participants using this feature are requested to dial into the
conference call fifteen minutes ahead of time to avoid delays.
An archived replay will also be available on the
“Events and Presentations” section of ReShape’s website at:
https://ir.reshapelifesciences.com/events-and-presentations.
About ReShape Lifesciences™
ReShape Lifesciences® is America’s premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved
Lap-Band® Program provides minimally invasive, long-term
treatment of obesity and is an alternative to more invasive
surgical stapling procedures such as the gastric bypass or sleeve
gastrectomy. ReShapeCare™ is a virtual weight-management program
that supports lifestyle changes for all weight loss patients led by
board-certified health coaches to help them keep the weight off
over time. The recently launched ReShape Marketplace™ is an online
collection of quality wellness products curated for all consumers
to help them achieve their health goals. The investigational
Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a
proprietary vagus nerve block and stimulation technology platform
for the treatment of Type 2 diabetes and metabolic disorders. The
Obalon® balloon technology is a non-surgical, swallowable,
gas-filled intra-gastric balloon that is designed to provide
long-lasting weight loss. For more information, please visit
www.reshapelifesciences.com.
CONTACTS:
Company Contact:Thomas
StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael Miller917-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
ReShape Lifesciences (NASDAQ:RSLS)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024